Could a heart drug boost bladder cancer treatment?
NCT ID NCT07353294
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding the blood pressure drug propranolol to standard immunotherapy and chemotherapy can help shrink bladder cancer that has spread to lymph nodes before surgery. The study enrolls 12 patients and primarily checks for safety and side effects. Researchers hope propranolol may overcome resistance in lymph node tumors by blocking stress signals.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
propranolol (a beta-blocker drug) combined with tislelizumab (an immunotherapy) and gemcitabine/cisplatin (chemotherapy)
What this could lead to
If successful, this could point toward a new treatment approach for bladder cancer that has spread to lymph nodes, potentially improving response rates.
What could go wrong
This is a very early phase 1 trial with only 12 participants, focused on safety. It is too small to prove effectiveness, and the combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510000, China